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Summary 24 
 25 
The advances in molecular biology of the last decades have dramatically improved the field of 26 
diagnostic bacteriology. In particular PCR-based technologies have impacted the diagnosis of 27 
infections caused by obligate intracellular bacteria such as pathogens from the Chlamydiacae 28 
family. Here, we describe a real-time PCR-based method using the Taqman technology for the 29 
diagnosis of Chlamydia pneumoniae, Chlamydia psittaci and Chlamydia abortus infection. The 30 
method presented here can be applied to various clinical samples and can be adapted on opened 31 
molecular diagnostic platforms. 32 
 33 
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1. Introduction 36 
Chlamydiacae are obligate intracellular bacteria, among which several species are pathogenic 37 
towards humans and can cause a broad range of diseases.  Chlamydia trachomatis is involved in 38 
urogenital infection as well as ocular, joint and oropharyngeal infections. Chlamydia 39 
pneumoniae and Chlamydia psittaci are primarily associated with community-acquired 40 
pneumonia (CAP). C. pneumoniae have been essentially associated with infections in humans [1] 41 
but some studies suggest an association with other mammals such as koalas [2-8]. C. 42 
pneumoniae might also be a causative agent of an asthma-like syndrome in children [9]. C. 43 
psittaci is the etiologic agent of a respiratory zoonosis transmitted by birds, in particular parrots 44 
and parakeets, but also chicken from the food industries as well as feral pigeons [2]. C. abortus is 45 
genetically closely related to C. psittaci but displays a distinct animal and tissue tropism as it can 46 
colonize the placenta of cows, goats, cattles, pigs and horses, which can lead to abortion. C. 47 
abortus can be transmitted to humans, for instance through the exposure to infected animal 48 
abortive tissues, with the same outcome for pregnant women [2]. 49 
The diagnosis of infections due to intracellular bacteria has been dramatically improved by PCR-50 
based methods developed in the last decades. This is particularly true for the diagnosis of C. 51 
trachomatis, for which several commercial systems have been developed. The laboratory of 52 
molecular diagnostic of the Institute of Microbiology of the Lausanne University Hospital 53 
(Lausanne, Switzerland), developed  a molecular diagnostic platform recently described by 54 
Greub and colleagues,  which allows one to perform multiple PCRs simultaneously targeting 55 
different pathogens, thanks to the standardisation of the parameters (i.e. amplicon length, and 56 
primers and probes Tm) of the reactions [10]. This molecular platform based on the Taqman-57 
probes technology (Applied Biosystems) allows for performance of up to 91 different PCR 58 
reactions corresponding to 69 pathogens and/or resistance genes in a single microplate [10]. 59 
Among them are a real-time PCR for the detection of C. pneumoniae [11] and a real-time duplex 60 
PCR for the detection of C. psittaci and C. abortus infection from various clinical samples 61 
(Table 1), both based on the Taqman probe technology [12]. The C. pneumoniae PCR is based 62 
on the pst1 gene and the C. psittaci-C. abortus duplex PCR was designed as follows: 1) PCR1 63 
targets a DNA sequence of the 16S–23S rRNA operon allowing the detection of both C. psittaci 64 
and C. abortus and 2) PCR 2 targets the coding DNA sequence CPSIT_0607 so far unique to C. 65 
psittaci [12]. In this chapter, the methods to achieve the C. pneumoniae PCR and the C. psittaci-66 
4 
 
C. abortus duplex PCR on an opened molecular diagnostic platform are detailed. For this 67 
specific chapter, part of the samples’ processing methods and infrastructure descriptions have 68 
been extracted from the accredited documentation of the Laboratory of Diagnostic of the 69 
Institute of Microbiology of the University of Lausanne.  70 
 71 
 72 
  73 
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 74 
2. Materials 75 
2.1 Laboratory organization 76 
All the procedures should be carried-out according to molecular diagnostic principles aimed to 77 
avoid contaminations with microorganisms or nucleic acids (See Note 1). 78 
  79 
2.2 Sample processing 80 
1. N-acetyl cysteine solution:  in a 50 ml conical tube, containing 1.0 g of N-acetyl cysteine, 81 
add 50 ml of Tris-Sodium-Citrate-di-hydrate buffer. The solution should be used the 82 
same day.  83 
2. Molecular biology grade PBS: DNase-Free, RNase-Free, does not contain detectable 84 
amounts of nucleic acid or any nucleic-acid extractions’ compatible molecular biology 85 
grade solution. 86 
 87 
2.3 Material for DNA extraction  88 
1. Several automated instruments exist for DNA extraction, in the Institute of microbiology, 89 
nucleic-acid extraction is achieved with the MagNA Pure 96R instrument (Roche): an 90 
automated system for the extraction of nucleic-acid from bacteria (as well as other 91 
microorganisms such as viruses) using a technology based on magnetic glass particles. 92 
The MagNA Pure 96R instrument reagents are those provided by the manufacturer. This 93 
nucleic-acid extraction instrument has been associated with a liquid handling distribution 94 
system, the STARletR instrument (HamiltonR) [13] (See Note 2).  95 
 96 
2. Molecular biology grade PBS: DNase-Free, RNase-Free, does not contain detectable 97 
amounts of nucleic acid or any nucleic-acid extractions’ compatible molecular biology 98 
grade solution. 99 
 100 
2.4 Assembly of the PCR plate and amplification  101 
 102 
1. TaqMan Universal Master Mix (Applied Biosystems). 103 
2. Primers and probes (Table 1).  104 
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3. Molecular biology grade water: DNase- and RNase-free water, which does not contain 105 
detectable amounts of nucleic acid. 106 
4. Positive control. The positive controls consist of synthetic plasmids containing the exact 107 
PCR amplicon [12,11]. 108 
5. PCR instrument (see Notes 3 and 4). 109 
 110 
3. Methods 111 
  112 
3.1 Sample processing  113 
In clinical practice, the detection of C. pneumoniae, C. psittaci and C. abortus can be achieved 114 
from a broad range of samples (Table 2). Depending on the nature of the sample (liquid, viscous 115 
or solid) a specific processing will be required either to concentrate (liquid samples) or to 116 
homogenize (viscous or solid samples) the specimen. 117 
 118 
1. Introduce the lab request into the laboratory information system (LIS) to generate the 119 
barcode labels necessary to manage tubes during the analytic process (See Note 5). 120 
2. For each sample, label three screw cap tubes (2ml) with the barcode as follows: one 121 
“native” tube, one “native-aliquot” tube and one “DNA tube”. 122 
3. Under the laminar flow dedicated for molecular diagnostics in the “specimen-receiving 123 
laboratory,” distribute the sample into the native-aliquot tube and the native tube. The 124 
native tube will be frozen at -80°C and kept as backup in case of need. If necessary 125 
several native tubes can be stored; a suggestion for biopsies would be to store both the 126 
native samples and the processed samples in distinct tubes.  The aliquot-native tube 127 
together with the DNA tube will be transported to the molecular diagnostic laboratory 128 
and used for nucleic acids extraction. Viscous samples such as respiratory secretions 129 
should be homogenized by liquefaction where as solid samples such as biopsies and 130 
fragments should be crushed as described below. 131 
4. Liquefaction of viscous secretions: respiratory secretions (sputum, bronchial aspirate, 132 
stomach tube) for the detection of C. pneumoniae and C. psittaci can be too viscous to be 133 
homogenized by simple vortexing. Liquefaction can be achieved using N-acetyl-L-134 
cysteine, a reducing substance having free thiol groups (-SH), to reduce specimen 135 
7 
 
viscosity by breaking the disulfide bonds of glycoproteins that constitute the bronchial 136 
mucus. Any other viscous fluids shall also be liquefied. To do so, visually control the 137 
viscosity of the sample; if liquefaction is necessary, transfer a suitable amount of the 138 
sample in a 15 or 50 ml conical tube using a single use plastic Pasteur pipette, under the 139 
hood with laminar flow. Add an equal amount of N-acetyl-L-cysteine solution. A larger 140 
amount of N-acetyl-L-cysteine solution can be needed for very sticky samples. Vortex 141 
and visually check the liquefaction of the sample and if necessary, leave the sample on a 142 
rotor for up to 30 minutes. At the end of the incubation, visually check the liquefaction of 143 
the sample and centrifuge the sample 30 minutes at 3000 g then remove the supernatant 144 
using a pipette with filter tips, leaving 1 to 2 mL of liquid in which the pellet will be 145 
resuspended. Transfer the amount necessary for nucleic acids extraction (more than 200 146 
µl) into the tube labelled as aliquot-native" (See Note 6), and keep the rest in the tube 147 
labelled as "native”. Store the native tube at -80°C in the core specimen receiving 148 
laboratory and transport the aliquot-native tube and the DNA tube to the molecular 149 
diagnostic laboratory. 150 
5. Crushing of solid specimens. Solid samples such as biopsies and fragments that cannot be 151 
homogenized either using the vortex or by liquefaction should be crushed as follows. 152 
Under the hood with laminar flow put the little pieces in the crushing device with part of 153 
the solution of the native sample (if any) or add a solution adapted to the DNA extractor 154 
(PBS) using a pipette with filtered tips (see Note 7). If the specimen is too big, take a 155 
piece of it with sterile forceps and place it in a sterile Petri dish to cut it into several small 156 
pieces. Crush a piece of the specimen and keep the rest in reserve. Start the crushing 157 
device. Generally, the fragments are successfully crushed, if not, this procedure is still 158 
sufficient to release microorganisms from the specimen by compression. In this case, 159 
avoiding some remaining large fragments, transfer the crushed sample (volume) in the 160 
aliquot-native tube, and the rest in the native tube for storage at -20°C. If necessary add 161 
some molecular biology grade water into the aliquot-native tube to reach the minimum 162 
volume suitable for nucleic acids extraction.  Vortex the tube. Transport the aliquot-163 
native tube and the DNA tube to the molecular diagnostic laboratory.  164 
 165 
3.2 DNA extraction 166 
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1. Using the STARletR liquid handling instrument, transfer 200 ul of the sample tube in the 167 
extraction plate of the MagNA Pure 96R instrument. 168 
2. Extraction control (EC). The EC corresponds to a tube submitted to the same extraction 169 
protocol that the clinical specimen but in which the volume of the clinical sample is 170 
replaced by an equal volume of a solution adapted to the DNA extractor (PBS). An 171 
extraction control is needed for each run of extraction (see Note 8). The extraction 172 
control must be negative when the PCR specific for the pathogen (s) tested is (are) made. 173 
3. Transfer the 96-well microplate into the MagNAPure 96R instrument and start the nucleic 174 
acids extraction program according to the user manual. Nucleic acids can be eluted either 175 
in 50µl or 100µl of elution buffer depending on the chosen program and are maintained 176 
at 4°C (See Note 9). 177 
 178 
3.3 Preparation of the PCR controls 179 
1. Negative control of PCR. Each run of amplification should contain a PCR negative 180 
control that consists of the extraction control used as a template. The negative control is 181 
used to test the reactivity of the component of the reaction mixture. It should not be 182 
contaminated with target DNA and should not allow non-specific amplification. 183 
2. Positive control. Positive controls consist of synthetic plasmid DNA containing the target 184 
sequence of the PCRs [12,11] (See Note 10). For each run of PCR, three reactions with 185 
three dilutions of the positive controls containing 10, 102 and 103 DNA copies per 186 
reaction should be added. They will serve both to generate the standard curve that will be 187 
used for the quantification of the positive control and to determine the sensitivity of the 188 
reaction based on the positive amplification, the reaction containing 10 copies of DNA.  189 
3. Inhibition control. The presence of PCR inhibitors should be tested for each sample. To 190 
do so the inhibition control reaction consists of a reaction in which 200 copies of the 191 
positive control is added to the reaction mixture containing the DNA specimen to be 192 
tested [10]. 193 
 194 
3.4 Preparation of the PCR mix, design and assembly of the PCR microplate and 195 
amplification 196 
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1. Design of the Taqman PCR plate. This can be achieved using dedicated software such as 197 
the SDS 2.4.1 software (Applied Biosystems) allowing the design of either 96 or 384 well 198 
PCR plates [10]. The same final volume (20 µl) is convenient for both type of plate. It is 199 
strongly recommended to do each analysis in duplicate (or even in triplicate). When an 200 
internal control is not used, an additional well for the inhibition control is needed, if not 201 
using internal inhibition control. Moreover, there is a need for at least one well for the 202 
inhibition control, one well for the negative control and 3 wells for the standard curve. A 203 
standard curve is required for each PCR. One regression curve is required for the PCR1 204 
and another for the PCR2 [12].  205 
2. In the DNA-free laboratory, prepare the PCR mix. A single mix is needed for the 206 
detection of C. psittaci and C. abortus.  In a final volume of 20 µl, add 5 µl of the 207 
extracted DNA, the forward and reverse primers and the probes at the final concentration 208 
indicated in table 2. The inhibition control reaction consists of the same reaction in 209 
which, 200 copies of the control plasmids are added.  As an extraction negative control 210 
the DNA is replaced by the same volume of the extraction control. As a negative control 211 
of the PCR, the DNA is replaced by molecular grade water.  212 
3. Assembly of the PCR plate. The assembly of the PCR plate can be done manually for 96 213 
well plates (See Note 11) or using automated instruments for 384 well plates [10]. The 214 
reactions are achieved in a final volume of 20 µl with 5 µl of DNA sample [12,11]. 215 
4. Amplification.  Run the ABI 7900 instrument or similar thermocycler using the following 216 
cycling conditions: 2 min at 50°C, 10 min at 95°C followed by 45 cycles of 15s at 95°C 217 
and 1min sec at 60°C. 218 
 219 
3.5 Interpretation of the results 220 
The SDS 2.4.1 software is used for analysis and interpretation of the results. 221 
The results (qualitative and quantitative) are then checked and introduced into the LIS system. 222 
At the end of the process the final results are validated by a clinical microbiologist. 223 
 224 
1. Analyze the results of the positive controls with adequate software [10]. 225 
2. Internal quality control. For an analysis to be valid: a) the run should pass the internal 226 
quality control and b) the positive controls 10 copies must be detected. 227 
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3. Negative controls. Control that there is no amplification in the negative control reaction. 228 
4. Inhibition control. Control that there is amplification in the inhibition control tube 229 
containing 200 copies of the positive control plasmid (at least of 50 copies).  230 
5. Positive result. A result is positive if the fluorescence reaches the threshold automatically 231 
set by the software or manually set by the user according to the instrument.  232 
6. Interpretation of the C. psittaci-C. abortus PCR (See Note 12). 233 
7. If you suspect a contamination, when for instance only 1 reaction out of 3 reactions is 234 
positive or when amplification occurs in the extraction control or in the PCR negative 235 
control, you can follow the procedure described by Greub and colleagues for these 236 
situations  [10]. 237 
 238 
4. Notes  239 
Note 1 240 
As described by Greub and colleagues it is important to organize the laboratory of molecular 241 
diagnostic  in different rooms/spaces corresponding to pre-amplification and post-amplification 242 
area [10]. Moreover, the processing of clinical samples in the laboratory where the samples are 243 
received should be achieved under a laminar flow dedicated for molecular diagnostics that is 244 
distinct from laminar flows dedicated for conventional culture based microbiology diagnostics. 245 
Sterile samples should also be processed in dedicated laminar flows. The use of disposable lab 246 
coats, gloves and pipettes with filter tips is recommended. Thus, we recommend the following 247 
infrastructures and instruments: A) the sample reception laboratory should be equipped with a 248 
hood with laminar flow and UV, a vortex, a crushing instrument, a centrifuge, disposable lab 249 
coats and gloves, pipettes and filter tips, 2ml screw cap micro-tubes, sterile forceps and sterile 250 
Petri dishes; B) the nucleic acids’ extraction laboratory should also be equipped with a hood with 251 
laminar flow and UV, a vortex, pipettes and filter tips, disposable lab coats and gloves without 252 
mineral powders such as talc to prevent any deposition in the extraction tubes; C) the PCR 253 
master-mix should be prepared in a DNA free laboratory equipped with a hood with UV but 254 
without laminar flow; for all the post extraction area, hood with laminar flow should be 255 
prohibited in order to avoid the deposition of nucleic acids (NA) in opened tested tubes. In 256 
addition, the following instruments should be available in this laboratory: a vortex, a micro-257 
centrifuge, micro-tubes (0.2, 0.7 and 1.5 ml), 2ml screwed tube, pipettes and filter tips (0-10, 2-258 
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20, 20-200 et 200-1000 µl); D) the positive control should be prepared and stored in a “DNA 259 
laboratory” equipped with a hood with UV but without laminar flow, a vortex, a micro-260 
centrifuge, micro-tubes, pipettes and filter tips; E) It is recommended to assemble the PCR plate 261 
a dedicated pre-amplification laboratory different from the positive control laboratory. 262 
 263 
Note 2: 264 
If processing a large number of samples, it is recommended to select automated distribution 265 
systems that can recognize bar-coded tubes. 266 
 267 
Note 3:  268 
The assembly of the PCR plate can be achieved manually for 96 well plates or alternatively can 269 
be done by automated instruments to increase the precision and to avoid mistakes, especially 270 
when preparing 384 well plates [10]. 271 
 272 
Note 4:  273 
The PCR conditions described herein for the detection of C. pneumoniae, C. psittaci and C. 274 
abortus have been optimized for the PCR instrument ABI 7900 HT (Applied Biosystems) [12]. 275 
The reagent concentrations and the amplification program should be adapted if using other 276 
instruments [10]. 277 
 278 
Note 5: 279 
Tubes management is crucial all along the analytic process to avoid major errors such as 280 
inversions or contaminations. We strongly recommend the use of barcoded tubes.  281 
 282 
Note 6:  283 
If using an automated system such as the STARletR instrument (HamiltonR), do not forget to 284 
provide the dead volume of the device.   285 
 286 
Note 7: 287 
To avoid the dilution of the specimen, which could negatively impact the sensitivity of the PCR, 288 
do not add too much solution for the crushing of the sample. 289 
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 290 
Note 8: 291 
We recommend placing the extraction control at the end of the series where contamination are 292 
more expected to occur rather than at the first position of a series.  293 
 294 
Note 9: 295 
It is recommended to store the DNA sample at -80 ° C. 296 
 297 
Note 10: 298 
The concentration (DNA copies per ml) of the positive control should be precisely determined. 299 
The stock solution of the positive control should be stored in a separate, dedicated room. 300 
 301 
Note 11: 302 
The assembly of the PCR plate can be achieved manually especially for 96 well plates. In the 303 
DNA free laboratory prepare the PCR mix without the DNA. Place a 96-well micro-plate on a 304 
chilled metal rack and distribute the PCR master mix in the 96-well plate according to the 305 
Taqman plate set-up. Add the molecular grade water to the corresponding wells (i.e in the 306 
negative controls) and transfer the plate with the chilled metal plate in the assembly laboratory. 307 
In the assembly laboratory, add the DNA samples starting with the extraction control to avoid 308 
any contamination at this stage. Close the tubes when the DNAs of a patient are pipette in order 309 
to avoid contamination by aerosols. Repeat this for all the patients’ DNAs. When all the patients’ 310 
DNAs are added, cover the corresponding wells and carefully add the positive control in the 311 
wells corresponding to the "inhibition control". It is important to avoid any contamination of the 312 
patients’ test-tube with the positive controls which would lead to false positive results. Exit the 313 
room with the plate in a chilled metal rack and transfer it to the amplification room where the 314 
thermocycler is located. 315 
 316 
Note 12: 317 
As described in Opota et al 2015, if both PCR are positive (PCR1 and PCR2) in a respiratory 318 
sample, this indicates the presence of C. psittaci DNA [12]. Samples positive for PCR1 and 319 
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negative for PCR2 can be considered as positive for C. psittaci for respiratory specimens and 320 
positive for C. abortus for genital specimens. 321 
 322 
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Tables 370 
 371 
Table 1: Primers and probes  
    
Pathogen  
Oligonucleotide 
name  
Target gene  Sequence (5'-3') 
Modification, 
fluorochrome 
Amplicon 
lengh 
Final  
Concentration 
(µM) 
  
C. pneumoniae  
CPTM1 pst1 gene CATGGTGTCATTCGCCAAGT -   0.2 
   
 
CPTM2 pst1 gene  CGTGTCGTCCAGCCATTT TA -   0.2 
   
 
CP pst1 gene  TCTACGTTGCCTCTAAGAGAAAACTTCAAGTTGGA 3'-VIC, 5'-TAMRA  82  0.1 
   
 
C. psittaci and 
C. abortus  
CPSI_F 16S-23S operon AAGGAGAGAGGCGCCCAA -   0.35 
   
 
CPSI_R_LNA 16S-23S operon CAA[C]CTAGTCAAACCGTCCTAA LNA   0.35 
   
 
CPSI_P_MGB 16S-23S operon ACTGGGATGAAGTCGTAAC FAM, DQ  133  0.2 
   
 
C. psittaci  
CPSI_00F CDS CPSI_0607 AGCATTAGCCAGCGCTTTAGA -   0.35 
   
 
CPSI_00R_147C/G CDS CPSI_0607 TCTCTGAGCAAAAAC/GACTGCGT -   0.35 
   
 
CPSI_00P_MGB CDS CPSI_0607 ACAAAGACCTGGCGAGTA  VIC, DQ  118  0.2  
   
 
        
LNA = Locked nucleic acid, MGB = Minor groove binder, FAM = 6-carboxy-fluorescein, VIC = TaqMan VIC reporter dye, DQ = Dark quencher, BHQ = Black hole quencher 
 
 372 
  373 
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Table 2. Clinical specimens and pathogens generally used for the diagnosis of Chlamydia infections  
 
          
Colonne1 Sample type C. pneumoniae C. psittaci C. trachomatis C. abortus 
Oral Mouth swab     x   
Respiratory specimen Nasal swab  x x 
  Respiratory specimen Nasopharyngeal seretions  x x 
  Respiratory specimen Sputum x x 
  Respiratory specimen Bronchial secretion  x x 
  Respiratory specimen Bronchoalveolar lavage x x 
  Urogenital specimen Uterus and urethral smear  
  
x x 
Urogenital specimen Urethral swab 
  
x 
 Urogenital specimen Prostate biopsies 
  
x 
 Urogenital specimen Fragment  of  placenta 
  
x x 
Anal Anal swab 
  
x 
 Osteo-articular Joint fluid 
  
x 
 Osteo-articular Prosthetic fragment 
  
x 
 Vascular Drain fluid from aortic valve 
    Animal specimen Bird spleen 
 
x 
  Animal specimen Birds choanal or cloacal swabs  x 
  Animal specimen Fragment  of sheep placenta 
   
x 
      Non-comprehensive list  
     374 
